The association of nonsteroidal anti-inflammatory drugs (NSAIDs) and breast cancer risk was examined in a case-control study of 303 breast cancer patients and 906 population control subjects. Breast cancer cases reported a significantly lower frequency of regular NSAID use than controls (19.1% versus 26.8%, p<0.01) and the resulting odds ratio adjusted for other risk factors was significantly less than 1 (OR=0.65, 95% CI=0.5-0.9, p<0.01). Regular intake of NSAIDs (greater than or equal to 3 times per week for greater than or equal to 6 months) was associated with a 36% reduction in the risk of breast cancer (OR=0.64, 95% CI=0.4-0.9, p<0.01). Greater use (greater than or equal to 7 times per week for greater than or equal to 5 years) resulted in a 40% risk reduction (OR=0.60, 95% CI=0.4-0.9, p<0.05). The observed effects of non-prescription and prescription NSAIDs were similar, although sample sizes were small for individual compounds. These results suggest that NSAIDs may have chemopreventive potential against the development of breast cancer.

Related Articles